Last reviewed · How we verify

NCT05734716: COAST

Colorado-Oregon Altitude Study

Completed Phase 4 Last updated 10 March 2023
What this trial tests

Phase 4 trial testing Erythropoietin in Acute Mountain Sickness in 121 participants. Completed in 1 January 2023.

Timeline
17 February 2021
Primary endpoint
1 August 2022
1 January 2023

Quick facts

Lead sponsorUniversity of Oregon
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposebasic science
Enrollment121
Start date17 February 2021
Primary completion1 August 2022
Estimated completion1 January 2023
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Oregon

Who can join

Adults 18 to 40, any sex, with Acute Mountain Sickness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigating the utility of prophylactic treatment with iron sucrose and/or erythropoietin on the prevention of acute mountain sickness in fit, young, healthy individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Erythropoietin

Trials testing the same drug.

Other recruiting trials for Acute Mountain Sickness

Currently open trials in the same condition.

Other University of Oregon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing